Q1 EPS Estimates for Nurix Therapeutics Cut by HC Wainwright

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.72) per share for the quarter, down from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.00) EPS.

Other analysts have also recently issued reports about the stock. UBS Group initiated coverage on shares of Nurix Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $35.00 price objective for the company. Stephens reissued an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. BTIG Research started coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price objective on the stock. Stifel Nicolaus boosted their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Needham & Company LLC lowered their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.71.

Nurix Therapeutics Stock Down 1.5 %

Shares of Nurix Therapeutics stock opened at $19.71 on Friday. Nurix Therapeutics has a 12-month low of $7.79 and a 12-month high of $29.56. The stock has a 50 day moving average price of $20.09 and a two-hundred day moving average price of $22.39. The stock has a market capitalization of $1.50 billion, a P/E ratio of -6.82 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.38% and a negative net margin of 354.85%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NRIX. Rhumbline Advisers grew its holdings in Nurix Therapeutics by 13.5% during the 4th quarter. Rhumbline Advisers now owns 103,233 shares of the company’s stock worth $1,945,000 after acquiring an additional 12,315 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 21.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company’s stock valued at $283,000 after purchasing an additional 2,632 shares in the last quarter. SG Americas Securities LLC raised its position in Nurix Therapeutics by 31.1% in the 4th quarter. SG Americas Securities LLC now owns 30,086 shares of the company’s stock worth $567,000 after purchasing an additional 7,141 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Nurix Therapeutics by 85.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock worth $1,531,000 after buying an additional 31,352 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.